Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality?

Bibliography

• Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-63
   PubMed Web of Science ®Google Scholar
• Ogura H, Hasegawa A, Suami T. Carbohydrates: synthetic methods and applications in medicinal chemistry. Kodansha; Tokyo: 1992
   Google Scholar
• Lane DA, Lindahl U. Heparin: chemical and biological properties, clinical applications. Edward Arnold; London: 1989
   Google Scholar
• Hoppensteadt D, Walenga JM, Fareed J, et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am 2003;17:313-42
   PubMed Web of Science ®Google Scholar
• Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001;57:159-206
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin. N Engl J Med 1991;324:1565-74
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;126:188S-203S
   PubMed Web of Science ®Google Scholar
• Turpie AG. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg 1991;161:532-6
   PubMed Web of Science ®Google Scholar
• Samama CM, Barre E, Combe S, et al. A pilot study on the use of a low molecular weight heparin (Enoxaparin) in arterial reconstructive surgery. Semin Thromb Hemost 1991;17:367-70
   PubMed Web of Science ®Google Scholar
• Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976;69:570-7
   PubMed Web of Science ®Google Scholar
• Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22
   PubMed Web of Science ®Google Scholar
• Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208
   PubMedGoogle Scholar
• Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-8
   PubMed Web of Science ®Google Scholar
• Casu B, Petitou M, Provasoli M, et al. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 1988;13:221-5
   PubMed Web of Science ®Google Scholar
• Garg HG, Yu L, Hales CA, et al. Sulfation patterns in heparin and heparan sulfate: effects on the proliferation of bovine pulmonary artery smooth muscle cells. Biochim Biophys Acta 2003;1639:225-31
   PubMed Web of Science ®Google Scholar
• Ishihara M. Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 1994;4:817-24
   PubMed Web of Science ®Google Scholar
• Ono K, Hattori H, Takeshita S, et al. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999;9:705-11
   PubMed Web of Science ®Google Scholar
• Shifren A, Witt C, Christie C, et al. Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo) 2012;2012:316049
   PubMedGoogle Scholar
• Ozier A, Allard B, Bara I, et al. The pivotal role of airway smooth muscle in asthma pathophysiology. Hindawi Publishing Corporation; J Allergy (Cairo) 2011, doi:10.1155/2011/742710
   PubMedGoogle Scholar
• Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999;104:1001-6
   PubMed Web of Science ®Google Scholar
• Jarjour NN, Kelly E. Pathogenesis of asthma. Med Clin North Am 2002;86:925
   PubMed Web of Science ®Google Scholar
• Grootendorst D, Sont J, Willems L, et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997;27:769-79
   PubMed Web of Science ®Google Scholar
• Bloemen K, Verstraelen S, Van Den Heuvel R, et al. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol Lett 2007;113:6-18
   PubMed Web of Science ®Google Scholar
• Holgate ST, Davies DE, Lackie PM, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin immunol 2000;105:193-204
   PubMed Web of Science ®Google Scholar
• Holt PG. Antigen presentation in the lung. Am J Respir Crit Care Med 2000;162:S151-S56
   PubMed Web of Science ®Google Scholar
• Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999;402:18-23
   PubMed Web of Science ®Google Scholar
• Corrigan C, Kay A. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992;13:501-7
   PubMedGoogle Scholar
• Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin immunol 2001;108:S65-71
   PubMed Web of Science ®Google Scholar
• Bradding P, Holgate ST. Immunopathology and human mast cell cytokines. Crit Rev Oncol Hematol 1999;31:119
   PubMed Web of Science ®Google Scholar
• Parameswaran K, Willems-Widyastuti A, Alagappan VK, et al. Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys 2006;44:139-46
   Google Scholar
• Boxall C, Holgate S, Davies D. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J 2006;27:208-29
   PubMed Web of Science ®Google Scholar
• Nader H, Dietrich C. Natural occurrence and possible biological role of heparin. In: Lane D, Lindahl U, editors. Heparin: chemical and biological properties, clinical applications. Edward Arnold; London: 1989. p. 81-96
   Google Scholar
• Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L-and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-8
   PubMed Web of Science ®Google Scholar
• Lasser E, Simon R, Lyon S, et al. Heparin-like anticoagulants in asthma. Allergy 1987;42:619-25
   PubMed Web of Science ®Google Scholar
• Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am J Respir Crit Care Med 1993;147:160-3
   PubMed Web of Science ®Google Scholar
• Brown RA, Allegra L, Matera MG, et al. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 2006;19:419-24
   PubMed Web of Science ®Google Scholar
• Lider O, Mekori YA, Miller T, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990;20:493-9
   PubMed Web of Science ®Google Scholar
• Sasaki M, Herd CM, Page CP. Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 1993;110:107-12
   PubMed Web of Science ®Google Scholar
• Okona-Mensah K, Shittu E, Page C, et al. Inhibition of serum and transforming growth factor beta (TGF-beta1)-induced DNA synthesis in confluent airway smooth muscle by heparin. Br J Pharmacol 1998;125:599-606
   PubMed Web of Science ®Google Scholar
• Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993;329:90-5
   PubMed Web of Science ®Google Scholar
• Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 1999;160:576-81
   PubMed Web of Science ®Google Scholar
• Diamant Z, Timmers MC, Van der Veen H, et al. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996;153:1790-5
   PubMed Web of Science ®Google Scholar
• Motojima S, Frigas E, Loegering DA, et al. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am J Respir Crit Care Med 1989;139:801-5
   PubMed Web of Science ®Google Scholar
• Venge R, Byström J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29:1172-86
   PubMed Web of Science ®Google Scholar
• Bock P, Luscombe M, Marshall S, et al. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 1980;191:769
   PubMed Web of Science ®Google Scholar
• Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009;105:223-30
   PubMed Web of Science ®Google Scholar
• Lever R, Hoult JRS, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-40
   PubMed Web of Science ®Google Scholar
• Silvestro L, Viano I, Macario M, et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost 1994;20:254-8
   PubMed Web of Science ®Google Scholar
• Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest 2002;110:127-36
   PubMed Web of Science ®Google Scholar
• Lakshmi T, Shanmugasundaram N, Shanmuganathan S, et al. Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin. J Biomed Mater Res A 2010;95:118-28
   PubMedGoogle Scholar
• Peter K, Schwarz M, Conradt C, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation 1999;100:1533-9
   PubMed Web of Science ®Google Scholar
• Forrest M, Paulson JC. Selectin family of adhesion molecules. In: Granger DN, Schmid-Schoenbein GW, editors. Physiology and pathophisiology of leukocyte adhesion. Oxford University Press; New York: 1995. p. 43-82
   Google Scholar
• Koenig A, Norgard-Sumnicht K, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-89
   PubMed Web of Science ®Google Scholar
• Skinner MP, Lucas C, Burns G, et al. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 1991;266:5371-4
   PubMed Web of Science ®Google Scholar
• Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991;65:859-73
   PubMed Web of Science ®Google Scholar
• Adams DH, Rlloyd A. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997;349:490-5
   PubMed Web of Science ®Google Scholar
• Johnson Z, Proudfoot A, Handel T. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005;16:625-36
   PubMed Web of Science ®Google Scholar
• Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001;14:249-54
   PubMed Web of Science ®Google Scholar
• Kuschert GS, Coulin F, Power CA, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68
   PubMed Web of Science ®Google Scholar
• Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-7
   PubMed Web of Science ®Google Scholar
• Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear Factor-KappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71
   PubMed Web of Science ®Google Scholar
• Gagliardo R, Chanez P, Mathieu M, et al. Persistent activation of nuclear factor–kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 2003;168:1190-8
   PubMed Web of Science ®Google Scholar
• Li X, Zheng Z, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell. Cytokine 2012;60:114-21
   PubMed Web of Science ®Google Scholar
• Hecht I, Hershkoviz R, Shivtiel S, et al. Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol 2004;75:1139-46
   PubMed Web of Science ®Google Scholar
• Lucio J, D'Brot J, Guo C, et al. Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol 1992;73:1093-101
   PubMed Web of Science ®Google Scholar
• Page C. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by β2-agonists. Lancet 1991;337:717-20
   PubMed Web of Science ®Google Scholar
• Bissonnette E, Befus A. Mast cells in asthma. Can Respir J 1998;5:23
   PubMedGoogle Scholar
• Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1alpha, IL-1beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992;22:3027-31
   PubMed Web of Science ®Google Scholar
• Ji S-L, Cui H-F, Shi F, et al. Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes. World J Gastroenterol 2004;10:3490-4
   PubMed Web of Science ®Google Scholar
• Ramdin L, Perks B, Sheron N, et al. Regulation of interleukin-8 binding and function by heparin and a2-macroglobulin. Clin Exp Allergy 1998;28:616-24
   PubMed Web of Science ®Google Scholar
• Salek-Ardakani S, Arrand JR, Shaw D, et al. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood 2000;96:1879-88
   PubMed Web of Science ®Google Scholar
• Hasan M, Najjam S, Gordon MY, et al. IL-12 is a heparin-binding cytokine. J Immunol 1999;162:1064-70
   PubMed Web of Science ®Google Scholar
• Salas Martínez A, Sans i Cuffí M, Soriano A, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96
   PubMed Web of Science ®Google Scholar
• Koopmann W, Krangel MS. Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1alpha. J Biol Chem 1997;272:10103-9
   PubMed Web of Science ®Google Scholar
• Koopmann W, Ediriwickrema C, Krangel MS. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1beta. J Immunol 1999;163:2120-7
   PubMed Web of Science ®Google Scholar
• Proudfoot AE, Fritchley S, Borlat F, et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001;276:10620-6
   PubMed Web of Science ®Google Scholar
• Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology 1993;3:271-7
   PubMed Web of Science ®Google Scholar
• Guimond S, Maccarana M, Olwin B, et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993;268:23906-14
   PubMed Web of Science ®Google Scholar
• Martino MM, Briquez PS, Ranga A, et al. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci USA 2013;110:4563-8
   PubMed Web of Science ®Google Scholar
• Ermolieff J, Duranton J, Petitou M, et al. Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: potent effect of O-butyrylated heparin. Biochem J 1998;330:1369-74
   PubMed Web of Science ®Google Scholar
• Redini F, Tixier J, Petitou M, et al. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 1988;252:515-19
   PubMed Web of Science ®Google Scholar
• Fath MA, Wu X, Hileman RE, et al. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J Biol Chem 1998;273:13563-9
   PubMed Web of Science ®Google Scholar
• Butterworth AE, Wassom DL, Gleich GJ, et al. Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol 1979;122:221-9
   PubMed Web of Science ®Google Scholar
• Nilsson L, Peterson C, Venge P, et al. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg 1995;59:713-16
   PubMed Web of Science ®Google Scholar
• Page C. Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol 2013;2013:910743
   PubMedGoogle Scholar
• Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;368:780-93
   PubMed Web of Science ®Google Scholar
• Kilfeather S, Tagoe S, Perez A, et al. Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br J Pharmacol 1995;114:1442-6
   PubMed Web of Science ®Google Scholar
• Wright T, Castellot J, Petitou M, et al. Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge. J Biol Chem 1989;264:1534-42
   PubMed Web of Science ®Google Scholar
• Castellot JJ, Karnovsky MJ, Beeler DL, et al. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984;120:315-20
   PubMed Web of Science ®Google Scholar
• Fryer A, Huang Y-C, Rao G, et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997;282:208-19
   PubMed Web of Science ®Google Scholar
• Besner GE, Whelton D, Crissman-Combs MA, et al. Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments. Growth Factors 1992;7:289-96
   PubMed Web of Science ®Google Scholar
• Kalmes A, Vesti BR, Daum G, et al. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 2000;87:92-8
   PubMed Web of Science ®Google Scholar
• Dolowitz D, Dougherty T. The use of heparin as an anti-inflammatory agent. Laryngoscope 1960;70:873
   PubMedGoogle Scholar
• Ceyhan B, Celikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 1995;107:1009-12
   PubMed Web of Science ®Google Scholar
• Crimi N, Armato F, Lamicela M, et al. Inhibitory effect of heparin on eosinophil recruitment after nasal allergen challenge. Eur Respir J 1995;8:10s
   PubMedGoogle Scholar
• Bendstrup KE, Chambers CB, Jensen JI, et al. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999;160:1653-8
   PubMed Web of Science ®Google Scholar
• Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998;34:135-54
   PubMed Web of Science ®Google Scholar
• Baughman RA, Kapoor SC, Agarwal RK, et al. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 1998;98:1610-15
   PubMed Web of Science ®Google Scholar
• Ahmed T, Smith G, Abraham WM. Effect of oral and intravenous heparin tetrasaccharide on allergic airway responses: critical role of N-sulfation. Pulm Pharmacol Ther 2013;26:180-8
   PubMed Web of Science ®Google Scholar
• Shastri MD, Johns C, Hutchinson JP, et al. Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties. Anal Bioanal Chem 2013;405:6043-52
   PubMed Web of Science ®Google Scholar
• O'Donnell W, Rosenberg M, Kelleher K, et al. Inhaled heparin does not protect asthmatics against antigen-induced bronchoconstriction. Am Rev Respir Dis 1992;145:A422
   Google Scholar
• Pavord I, Mudassar T, Bennett J, et al. The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Eur Respir J 1996;9:217-19
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb Haemost 2006;95:535
   PubMed Web of Science ®Google Scholar
• Simonis D, Christ K, Alban S, et al. Affinity and kinetics of different heparins binding to P-and L-selectin. Semin Thromb Hemost 2007;33:534-9
   PubMed Web of Science ®Google Scholar
• Chande N, MacDonald JK, Wang JJ, et al. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis 2011;17:1979-86
   PubMed Web of Science ®Google Scholar
• Hodak E, Yosipovitch G, David M, et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol 1998;38:564-8
   PubMed Web of Science ®Google Scholar
• Pervin A, Alhakim A, Linhardt R. Separation of glycosaminoglycan-derived oligosaccharides by capillary electrophoresis using reverse polarity. Anal Biochem 1994;221:182-8
   PubMed Web of Science ®Google Scholar
• Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109
   PubMed Web of Science ®Google Scholar
• Fareed J, Jeske W, Hoppensteadt D, et al. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998;82:3L-10L
   PubMed Web of Science ®Google Scholar
• Patel RP, Narkowicz C, Hutchinson JP, et al. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal 2008;46:30-5
   PubMed Web of Science ®Google Scholar
• Kennedy TP. Methods of treating acute exacerbations of chronic obstructive pulmonary disease. 20090054374; 2008
   Google Scholar
• Turnbull JE, Fernig D, Ke Y, et al. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992;267:10337-41
   PubMed Web of Science ®Google Scholar
• Patel RP, Narkowicz C, Jacobson GA. Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci 2009;98:1700-11
   PubMed Web of Science ®Google Scholar
• Patel RP, Narkowicz C, Jacobson GA. Investigation of freezing-and thawing-induced biological, chemical, and physical changes to enoxaparin solution. J Pharm Sci 2009;98:1118-28
   PubMed Web of Science ®Google Scholar
• Patel RP, Narkowicz C, Jacobson GA. Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins. Anal Biochem 2009;387:113-21
   PubMed Web of Science ®Google Scholar
• Langeslay DJ, Urso E, Gardini C, et al. Reversed-phase ion-pair ultra-high-performance-liquid chromatography–mass spectrometry for fingerprinting low-molecular-weight heparins. J Chromatogr A 2013;1292:201-10
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002
   PubMed Web of Science ®Google Scholar
• Wraight JM, Smith AD, Cowan JO, et al. Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology 2004;9:215-21
   PubMed Web of Science ®Google Scholar
• Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6
   PubMed Web of Science ®Google Scholar
• Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin immunol 2000;105:752-9
   PubMed Web of Science ®Google Scholar
• Djukanović R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74
   PubMed Web of Science ®Google Scholar
• Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208
   PubMed Web of Science ®Google Scholar
• Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5
   PubMed Web of Science ®Google Scholar
• Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000;106:E8
   PubMed Web of Science ®Google Scholar
• Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 1996;153:1702-7
   PubMed Web of Science ®Google Scholar
• Antczak M, Kuna P. Heparin inhibits allergen induced airway response in asthmatics. Results of a double blind placebo-controlled crossover study [abstract]. J Allergy Clin Immunol 1995;95:386
   Web of Science ®Google Scholar